Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

A novel approach to tumor-infiltrating lymphocyte therapy yielded higher response rates among patients with metastatic ...

Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 ...

The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

ALX Oncology (ALXO) announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company’s investigational CD47-blocker ...

Enfortumab vedotin plus pembrolizumab followed by surgery showed high complete response rates in advanced urothelial cancer.

Dana-Farber Brigham Cancer Center-led phase 3 clinical trial shows that pembrolizumab before and after standard-of-care surgery significantly extends ...

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck cancer, metastatic breast cancer and lung cancer.

Akeso (AKESF) announced that its “globally first-in-class PD-1/VEGF bispecific antibody,” ivonescimab, has received approval from the National ...